Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
In a first trial of androgen receptor inhibitor, enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer, pharmacokinetics and tolerability of single agentenzalutamide have shown to be similar to that reported in men.
Estradiol remained low in combination with exemestane, according to the results presented by Dr Tiffany Traina of the Memorial Sloan-Kettering Cancer Center, New York, USA.
Read the article in full here
Source: ESMO
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.